Brief: Gain Therapeutics Presents New Preclinical Data From Its Gaucher Disease Program
27/02/2023 13:57
Feb 27 (Reuters) - Gain Therapeutics Inc GANX.O :
* GAIN THERAPEUTICS PRESENTS NEW PRECLINICAL DATA FROM ITS
GAUCHER
DISEASE PROGRAM AT THE 19TH ANNUAL WORLDSYMPOSIUM
* REMAIN ON TRACK TO SUBMIT DOSSIER FOR START OF PHASE 1
CLINICAL
STUDY WITH OUR LEAD GCASE-TARGETING COMPOUND GT-02287 IN
MID-2023
Source text for Eikon: ID:nGNXScR63
Further company coverage: GANX.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Gain Therapeutics
See all newsU.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil
U.S. STOCKS ON THE MOVEX-Abbott, Columbia Financial, Jabil,
Gain Therapeutics climbs on narrower-than-expected quarterly loss
Gain Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Gain Therapeutics Q2 net loss per share narrows as R&D expenses fall